According
to a new market report published by Transparency Market Research
"Hemoglobin A1c Testing Devices Market (End-use-Laboratory and
Point-of-Care Testing Devices; Technologies - Ion-Exchange HPLC,
Immunoassay, Boronate Affinity Chromatography, Direct Enzymatic Assay
and Others) - Global Industry Analysis, Size, Share, Growth, Trends
and Forecast, 2013 - 2019,"theglobal hemoglobin A1c(HbA1c)
testing devices market was valued at USD 0.94billion in 2012 and is
expected to reach a value of USD 1.86 billion in 2019, growing at a
CAGR of 10.3% from 2013 to 2019.
Browse
the full Hemoglobin A1c Testing Devices Market report at
Measuring
glycated hemoglobin provides an average blood glucose level for the
past 2 to 3 months. This test provides a much reliable status of the
patient's condition rather than the conventional blood glucose tests.
With the advent of HbA1c testing for diagnosis of diabetes, the
overall diabetes diagnosis market is expected to undergo impressive
growth in the future. In addition, the demand for such devices is
bound to increase rapidly with rising awareness about diabetes
prevention and management. The rising global incidence rate of
diabetes and aging of population are the other major factors
contributing to the growth of this market.
Amongst
the two end-uses, the global hemoglobin A1ctestingdevices market was
dominated by laboratory testing devices with a market share of
approximately 66.2% in 2012,on account of high presence of these
devices in the developed markets which formed the major revenue base
for the global market players. Increase in awareness about HbA1c
testing will lead to growth in preference and prescription by
physicians and will thereby increase the demand for such testing
devices. However, the global market for point-of-care testing devices
will be the faster growing segments against laboratory testing.
Factors such as growth in home healthcare market, rising demand for
rapid and bed-side testing devices and growing need for early
diagnosis and efficient disease management will contribute to the
growth of this market segment during the forecast period.
Get
Free Sample Report at
http://www.transparencymarketresearch.com/hemoglobin-a1c-testing.html
The
global hemoglobin A1ctestingdevices market by technology was
dominated by ion-exchange HPLC testing technology segment in 2012,on
account of its higher accuracy. Moreover, being the first technology
utilized for testing glycated hemoglobin, it is considered to be the
standard technology for HbA1c testing. In addition, it is used in
conjunction with other technologies to provide faster and more
accurate results. However, the boronate affinity chromatography
technology market will record the highest growth due to its highest
accuracy among all techniques and quick results. This technology is
observed to show no effect of any of the hemoglobin variants i.e. it
has no interference in test results from hemoglobin variants. It is
expected that during the forecast period 2013 - 2019, the global
boronate affinity chromatography technology market will grow at a
CAGR of 11.9%.
Browse
Medical Devices Market Research Reports @
http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html
North
America dominated the hemoglobin A1ctestingdevices market in 2012 and
is expected to maintain its lead position in the global market till
2019. However, the Asia-Pacific market is estimated to grow at a
higher CAGR of 12.2% from 2013 to 2019 due to increasing awareness
about accuracy and efficacy of hemoglobin A1ctesting, which will
drive the demand for HbA1c testing devices. India and China are the
leading countries in terms of diabetic population, and the
Asia-Pacific region shows a rapidly increasing incidence rate for
diabetes which will ensure a steady demand for a reliable and
effective HbA1c testing method. Some of the key players in the global
hemoglobin A1ctestingdevices market include Abbott Laboratories,
Alere, Inc., Arkray, Inc., Danaher Corporation, Bio-Rad Laboratories,
Inc., A. Menarini Diagnostics, F. Hoffmann-La Roche Ltd. and Siemens
Healthcare.
No comments:
Post a Comment